References
- Molica S, Giannarelli D, Levato L, et al. A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL). Int J Hematol 2014;100(3):290-5
- Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115(2):363-72
- Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109(11):4679-85
- Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014;124(1):49-62
- Lin TT, Norris K, Heppel NH, et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol 2014. [Epub ahead of print]
- Lin TT, Letsolo BT, Jones RE, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010;116(11):1899-907
- Shanafelt TD, Bowen DA, Venkat C, et al. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res 2009;33(2):263-70
- Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
- O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15(1):48-58
- Khan M, Saif A, Sandler S, Mirrakhimov AE. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol 2014;2014:931858